LUCIUS 卢修斯 替沃扎尼 Tivozanib肾细胞癌

替沃扎尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Tivozanib

老挝国家食药监局批准上市
老挝国家药检所检测认证

肾细胞癌

ca Lucit iNo capsule cootauns Img of Tivozanb
erochloride agurvalent to Tivoranb. 080me
Indicaton:

LUCIUS
PHARMACEUTICALS

Dosage ad se:
Recommended Dose: 1.34 mg once danly with or
without food for 21 dass on treatment folleuadk

LuciTivo

davs olf treatment (28 dnveuelA kl du
rruptions and or dose redaction may be

needed to marane adierve re
For patients snth modarta harslsr imndirn

Tivozanib Capsules

FDA批准

ge in a dry place and store at 20Cto 25
Maraing:

0.89mg

Keen medicine out of reach of Children
Do not ndiminictered LuciTivo in Pregnancy and
Lactation oatient frert
PLEASE SEE PACKAGE INSERT
Maznfactured ond Marketed by

Rx Only

LUCUS
Thongmang village. Xaythany district, Vientian
Canital. Laos

权威认证

Warnine: Tobe sold bu retail on d

e paysicians only. and as dirsttod

21 Capsules

口碑质量

适应症:

适用于治疗既往两次或多次全身治疗后复发或难治性晚期肾细胞
癌(RCC)的成年患者。
推荐剂量:
1、常规推荐剂量为1.34 mg,每天口服一次,治疗21天,然后停止
治疗7天,为期28天。继续治疗,直到疾病进展或出现不可接受的毒
性。
2、如果发生腹泻、恶心或呕吐等不良反应将剂量减少至0.89
mg,每天口服一次,治疗21天,然后停止治疗7天,为期28天。
3、对于中度肝损伤患者的推荐剂量是0.89 mg:每日口服一次,治

疗21天,然后停止治疗7天,为期28天。